Alibaba's financial services spinoff plans to float concurrently in Shanghai and Hong Kong, with China Life and China Post among the investors in line for exits.

The gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.

Novo-backed immuno-oncology drug developer Checkmate Pharmaceuticals has filed to go public a month after its last funding round.

UC Berkeley-linked cell biology technology developer Berkeley Lights floated in a $178m offering and its shares almost tripled in price on their first day of trading.

The Nikon and Varian-backed cell biology technology developer floated in a $178m offering and its shares almost tripled in price on their first day of trading.

The Roche and GSK-backed autoimmune disease drug developer has gone public in an upsized initial public offering after at least $138m in earlier funding.

The oncology therapy developer has gone public in an upsized offering that provided an exit to Third Rock Ventures.

The EV battery producer has gone public in China, weeks after raising $193m in a round featuring strategic partner Daimler.

The oncology therapy developer has gone public in an upsized offering that provided exits for SoftBank Vision Fund and Alphabet's GV unit.

UPMC's patient telemedicine service Curavi Health has completed a merger that enables its founding institution to retain an equity stake.